The global TNF alpha inhibitors market grew from US$ 40.73 billion in 2022. The global market is estimated to reach US$ 46.98 billion by 2031, growing at a CAGR of 1.6% during the forecast period from 2023 to 2031.
TNF alpha inhibitors are drugs that serve to lessen or stop inflammation and are used to treat inflammatory disorders such as rheumatoid arthritis (RA), psoriatic arthritis, and juvenile idiopathic arthritis. TNF blockers may make skin cancer more likely, especially non-melanoma skin malignancies like squamous cell carcinoma. Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cinzia (certolizumab pegol), and Simponi (golimumab) are the main TNF alpha inhibitor medication classes.
Factors Influencing Market Growth
Regional Analysis
North America is likely to hold a major market share in the global TNF inhibitors market throughout the forecast period. The domination is due to a number of elements, including regional accessibility to cutting-edge healthcare facilities and well-established direct reimbursement regulations.
The prevalence of autoimmune illnesses is rising around the globe, which is also fueling the market's expansion. For instance, the Crohn's and Colitis Foundation report from 2022 stated that 1.6 million Americans, the majority of whom are under 35, were affected with Crohn's disease and ulcerative colitis. In a similar vein, according to government statistics provided by Statistics Canada in August 2022, there were 6,087,600 cases of arthritis in Canada in 2021. The increasing frequency of autoimmune diseases in North American nations will increase demand for potent therapies and accelerate market expansion in this region.
Additionally, the regulatory authorities' accelerated process for product approval fuels global market growth. For instance, the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA (adalimumab-AFF) as an interchangeable biosimilar to Humira (adalimumab) was approved by the United States Food and Drug Administration (FDA) in February 2022.
Segmentation Analysis
Based on the disease type segment, psoriatic arthritis will grow at the highest CAGR during the forecast period. This is due to the increasing prevalence of the condition, rising consumer awareness by public and private awareness efforts, and advantageous reimbursement policies all contribute to the growth of the psoriasis industry.
Based on the drug segment, adalimumab is anticipated to have the highest market share. Adalimumab, marketed as Humira, is the first and only monoclonal antibody made entirely of human cells to be approved by the U.S. Food and Drug Administration for the treatment of rheumatoid arthritis.
Prominent Companies
Segmentation Outline
The global TNF alpha inhibitors market segmentation focuses on the Drug, Route of Administration, Disease Type, and Region.
By Drug
By Route of Administration
By Disease Type
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL TNF ALPHA INHIBITOR MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: TNF ALPHA INHIBITOR MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL TNF ALPHA INHIBITOR MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL TNF ALPHA INHIBITOR MARKET, BY DRUG
5.1 OVERVIEW
5.2 REMICADE (INFLIXIMAB)
5.3 ENBREL (ETANERCEPT)
5.4 HUMIRA (ADALIMUMAB)
5.5 CIMZIA (CERTOLIZUMAB PEGOL)
5.6 SIMPONI (GOLIMUMAB)
6 GLOBAL TNF ALPHA INHIBITOR MARKET, BY ROUTE OF ADMINISTRATION
6.1 OVERVIEW
6.2 ORAL
6.3 SUBCUTANEOUS
6.4 INTRAVENOUS
6.5 OTHER ROUTE OF ADMINISTRATION
7 GLOBAL TNF ALPHA INHIBITOR MARKET, BY DISEASE TYPE
7.1 OVERVIEW
7.2 INFLAMMATORY BOWEL DISEASE
7.3 PSORIATIC ARTHRITIS
7.4 ULCERATIVE COLITIS (UC)
7.5 RHEUMATOID ARTHRITIS
7.6 ANKYLOSING SPONDYLITIS
7.8 OTHER DISEASE TYPES
8 GLOBAL TNF ALPHA INHIBITOR MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3. 1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL TNF ALPHA INHIBITOR MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 ABBVIE INC.
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 AMGEN INC.
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 INNOVENT BIOLOGICS, INC.
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 NOVARTIS INTERNATIONAL AG
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 PFIZER, INC.
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 MERCK & CO., INC.
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 BIOCAD BIOPHARMACEUTICAL CO.
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
著作権 ©2022 無断複写・転載を禁じます